Resistance To Tyrosine Kinase Inhibitors
Download Resistance To Tyrosine Kinase Inhibitors full books in PDF, epub, and Kindle. Read online free Resistance To Tyrosine Kinase Inhibitors ebook anywhere anytime directly on your device. Fast Download speed and no annoying ads. We cannot guarantee that every ebooks is available!
Resistance to Tyrosine Kinase Inhibitors
Author | : Daniele Focosi |
Publsiher | : Springer |
Total Pages | : 188 |
Release | : 2016-11-07 |
Genre | : Medical |
ISBN | : 9783319460918 |
Download Resistance to Tyrosine Kinase Inhibitors Book in PDF, Epub and Kindle
The volume will serve as a primer on tyrosine kinase signaling and its importance in cancer. The volume will first introduce the common denominators of small-molecule and antibody-derived inhibitors, as well as the general phenomenon of resistance. The volume will then detail resistance to the most commonly used classes of tyrosine kinase inhibitors, and will focus specific chapters on resistance to BCR-ABL1, FLT3, angiokinase family members, and ALK inhibitors.
Tyrosine Kinases as Druggable Targets in Cancer
Author | : Huan Ren |
Publsiher | : BoD – Books on Demand |
Total Pages | : 136 |
Release | : 2019-09-25 |
Genre | : Medical |
ISBN | : 9781789848083 |
Download Tyrosine Kinases as Druggable Targets in Cancer Book in PDF, Epub and Kindle
Protein tyrosine kinase (PTK) deregulation contributes to growth of cancer and many other diseases. The development of small-molecule tyrosine kinase inhibitors (TKIs) that target the deregulated PTKs, such as epidermal growth factor receptor (EGFR) in non-small-cell lung cancer (NSCLC) and Bcr-ABL in chronic myeloid leukemia (CML), has revolutionized disease management. In this book, we examine a few aspects of PTKs and cancer, considering efficacy, predictive markers to therapeutic response, limitations, and future directions in TKI treatment. In this rapidly evolving field, overcoming therapeutic resistance is most challenging, and multi-targeting directs the next-generation TKIs and combination therapy as ongoing strategies in cancer treatment.
Protein Tyrosine Kinases
Author | : Doriano Fabbro,Frank McCormick |
Publsiher | : Springer Science & Business Media |
Total Pages | : 599 |
Release | : 2007-11-13 |
Genre | : Science |
ISBN | : 9781592599622 |
Download Protein Tyrosine Kinases Book in PDF, Epub and Kindle
Leading researchers, from the Novartis group that pioneered Gleevec/GlivecTM and around the world, comprehensively survey the state of the art in the drug discovery processes (bio- and chemoinformatics, structural biology, profiling, generation of resistance, etc.) aimed at generating PTK inhibitors for the treatment of various diseases, including cancer. Highlights include a discussion of the rationale and the progress made towards generating "selective" low molecular-weight kinase inhibitors; an analysis of the normal function, role in disease, and application of platelet-derived growth factor antagonists; and a summary of the factors involved in successful structure-based drug design. Additional chapters address the advantages and disadvantages of in vivo preclinical models for testing protein kinase inhibitors with antitumor activity and the utility of different methods in the drug discovery and development process for determining "on-target" vs "off-target" effects of kinase inhibitors.
Resistance to Anti Cancer Therapeutics Targeting Receptor Tyrosine Kinases and Downstream Pathways
Author | : Yosef Yarden,Moshe Elkabets |
Publsiher | : Springer |
Total Pages | : 242 |
Release | : 2018-03-28 |
Genre | : Medical |
ISBN | : 9783319679327 |
Download Resistance to Anti Cancer Therapeutics Targeting Receptor Tyrosine Kinases and Downstream Pathways Book in PDF, Epub and Kindle
This volume comprehensively covers the multiplicity and diversity of mechanisms underlying patient resistance to currently approved anti-cancer drugs, including tyrosine kinase inhibitors and monoclonal antibodies, blockers of growth factor receptors and their downstream pathways, which play essential functions in cancer progression. Each chapter will cover a specific group of targets and the cognate drugs, along with molecular modes of innate and evolving resistance.
Protein Kinase Inhibitors as Sensitizing Agents for Chemotherapy
Author | : Anonim |
Publsiher | : Academic Press |
Total Pages | : 292 |
Release | : 2018-11-21 |
Genre | : Medical |
ISBN | : 9780128127384 |
Download Protein Kinase Inhibitors as Sensitizing Agents for Chemotherapy Book in PDF, Epub and Kindle
Tyrosine Kinase Inhibitors as Sensitizing Agents for Chemotherapy, the fourth volume in the Cancer Sensitizing Agents for Chemotherapy Series, focuses on strategic combination therapies that involve a variety of tyrosine kinase inhibitors working together to overcome multi-drug resistance in cancer cells. The book discusses several tyrosine kinase inhibitors that have been used as sensitizing agents, such as EGFR, BCR-ABL, ALK and BRAF. In each chapter, readers will find comprehensive knowledge on the inhibitor and its action, including its biochemical, genetic, and molecular mechanisms' emphases. This book is a valuable source for oncologists, cancer researchers and those interested in applying new sensitizing agents to their research in clinical practice and in trials. Summarizes the sensitizing role of some tyrosine kinase inhibitors in existing research Brings recent findings in several cancer types, both experimental and clinically, with a particular emphases on underlying biochemical, genetic, and molecular mechanisms Provides an updated and comprehensive knowledge regarding the field of combinational cancer treatment
Allogeneic Stem Cell Transplantation
Author | : Hillard M. Lazarus,Mary J. Laughlin |
Publsiher | : Springer Science & Business Media |
Total Pages | : 881 |
Release | : 2010-03-02 |
Genre | : Medical |
ISBN | : 9781597454780 |
Download Allogeneic Stem Cell Transplantation Book in PDF, Epub and Kindle
Since the original publication of Allogeneic Stem Cell Transplantation: Clinical Research and Practice, Allogeneic hematopoietic stem cell transplantation (HSC) has undergone several fast-paced changes. In this second edition, the editors have focused on topics relevant to evolving knowledge in the field in order to better guide clinicians in decision-making and management of their patients, as well as help lead laboratory investigators in new directions emanating from clinical observations. Some of the most respected clinicians and scientists in this discipline have responded to the recent advances in the field by providing state-of-the-art discussions addressing these topics in the second edition. The text covers the scope of human genomic variation, the methods of HLA typing and interpretation of high-resolution HLA results. Comprehensive and up-to-date, Allogeneic Stem Cell Transplantation: Clinical Research and Practice, Second Edition offers concise advice on today's best clinical practice and will be of significant benefit to all clinicians and researchers in allogeneic HSC transplantation.
Tyrosine Kinase Inhibitors Advances in Research and Application 2012 Edition
Author | : Anonim |
Publsiher | : ScholarlyEditions |
Total Pages | : 66 |
Release | : 2012-12-26 |
Genre | : Medical |
ISBN | : 9781481611619 |
Download Tyrosine Kinase Inhibitors Advances in Research and Application 2012 Edition Book in PDF, Epub and Kindle
Tyrosine Kinase Inhibitors—Advances in Research and Application: 2012 Edition is a ScholarlyBrief™ that delivers timely, authoritative, comprehensive, and specialized information about Tyrosine Kinase Inhibitors in a concise format. The editors have built Tyrosine Kinase Inhibitors—Advances in Research and Application: 2012 Edition on the vast information databases of ScholarlyNews.™ You can expect the information about Tyrosine Kinase Inhibitors in this eBook to be deeper than what you can access anywhere else, as well as consistently reliable, authoritative, informed, and relevant. The content of Tyrosine Kinase Inhibitors—Advances in Research and Application: 2012 Edition has been produced by the world’s leading scientists, engineers, analysts, research institutions, and companies. All of the content is from peer-reviewed sources, and all of it is written, assembled, and edited by the editors at ScholarlyEditions™ and available exclusively from us. You now have a source you can cite with authority, confidence, and credibility. More information is available at http://www.ScholarlyEditions.com/.
Kinase Inhibitor Drugs
Author | : Rongshi Li,Jeffrey A. Stafford |
Publsiher | : John Wiley & Sons |
Total Pages | : 463 |
Release | : 2011-09-20 |
Genre | : Medical |
ISBN | : 9781118210901 |
Download Kinase Inhibitor Drugs Book in PDF, Epub and Kindle
A comprehensive resource on case studies of marketed kinase drugs and promising drug trials Since the discovery of protein kinase activity in 1954, the field of protein kinase drug discovery has advanced dramatically. With the ongoing clinical success of the Bcr-Abl kinase inhibitor Gleevec in the treatment of chronic myelogenous leukemia and seven additional marketed kinase inhibitor drugs, researchers have compelling evidence that kinase inhibitors can be highly efficacious in the treatment of diseases caused by aberrant activity of protein kinase. Currently more than 100 protein kinase inhibitors are in clinical development. In one comprehensive volume, the editors, Dr. Rongshi Li and Dr. Jeffrey Stafford, present timely and important case studies of marketed kinase drugs and several of the most advanced kinase inhibitors in clinical trials. Kinase Inhibitor Drugs includes: Case studies from leading investigators and experts in the field that provide firsthand accounts of kinase inhibitor discovery Current thinking on kinase structure, biochemistry, and signal transduction pathways Information on state-of-the-art technologies and tools such as structure-based and fragment-based drug discovery A lineup of clinical-phase growth factor receptor inhibitors Inhibitors of cell cycle kinases The discovery of allosteric inhibitors of MEK kinase Information on pharmacogenomics and its application to kinase inhibitor clinical development